Treatment of One and/or Two Level Cervical Degenerative Disc Disease
NCT ID: NCT05812092
Last Updated: 2025-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
50 participants
OBSERVATIONAL
2021-05-01
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of DEXA-C Anterior Cervical Interbody System
NCT05883436
Cervical Interbody Fusion Device Patient Registry
NCT05114356
Investigation of the Simplify® Cervical Artificial Disc
NCT02667067
The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
NCT05740176
Prospective Comparative Analysis of ACDF vs Fusion Interbody Cages With nanoLOCK Osseointegrative Technology
NCT05762055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DePuy Synthes Cervical Plating System
All enrolled patients will receive CONDUIT Interbody Cervical System with supplemental fixation using a DePuy Synthes Cervical Plating System.
CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System
CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System
CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of radiculopathy or myelopathy with radiculopathy of the cervical spine, with pain, paresthesias or paralysis in a specific nerve root distribution C2 through T1, including at least one of the following:
1. Neck and/or arm pain of at least 30/100 mm on the visual analogue scale (VAS) scale
2. Decreased muscle strength of at least one level on the clinical evaluation (0 to 5) scale
3. Abnormal sensation including hyperesthesia or hypoesthesia; and/or
4. Abnormal reflexes
3. Symptomatic cervical disc disease, facet arthropathy, or cervical spinal stenosis at 1 or 2 levels between C2 and T1, suitable for treatment with anterior discectomy, decompression, and fusion
4. Radiographically determined pathology at the level to be treated correlating to primary symptoms including at least one of the following:
1. Decreased disc height on radiography,) in comparison to a normal adjacent disc
2. Degenerative spondylosis
3. Disc herniation
5. NDI Score \>30%.
6. Unresponsive to non-operative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) for:
1. Approximately six weeks from radiculopathy or myelopathy with radiculopathy symptom onset; or
2. Have the presence of symptoms or signs of nerve root/spinal cord compression despite continued non-operative, conservative treatment; or
3. Sooner than 6 weeks for worsening symptoms of neurologic compromise.
7. Reported to be medically cleared for surgery.
8. Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.
9. Signed informed consent provided by subject.
Exclusion Criteria
2. Have a history of or anticipated treatment for active systemic infection, including HIV or Hepatitis C.
3. Have previous trauma to the C2 to T1 levels resulting in significant bony or disco- ligamentous cervical spine injury.
4. Have had any prior spine surgery at the operative level(s).
5. Have osteoporosis
6. Have Paget's disease of bone, osteomalacia or any other metabolic bone disease other than osteoporosis (addressed above).
7. Have active malignancy that included a history of any invasive malignancy (except non- melanoma skin cancer),unless the subject had been treated with curative intent and there had been no clinical signs or symptoms of the malignancy for at least five years.
8. Have symptomatic cervical disc disease or significant cervical spondylosis at more than 2 levels.
9. Have a known allergy to titanium.
10. Are currently pregnant or breastfeeding at time of enrollment or have plans to become pregnant within the next three years.
11. Have rheumatoid arthritis, lupus, or other autoimmune disease affecting the musculoskeletal system
12. Have diseases or conditions that would preclude accurate clinical evaluation in the opinion of the Investigator
13. Have concomitant conditions requiring daily, high-dose oral and/or inhaled steroids.
High dose steroid use is defined as:
1. Daily, chronic use of oral steroids equivalent to 5 mg/day of prednisone or greater.
2. Daily, chronic use of inhaled corticosteroids (at least twice per day).
3. Use of short-term (less than 10 days) oral steroids at a daily dose greater than 40mg prednisone equivalent within one month of the study procedure.
14. Have current or recent history (within 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) requiring intervention.
15. Have a Body Mass Index (BMI) \> 40 kg/m2.
16. Taking medications known to potentially interfere with bone/soft tissue healing (e.g., high-dose oral and/or inhaled steroids, immunosuppressant medication, chemotherapeutic agents). High dose steroid use as defined in Exclusion Criterion 13.
17. Have pending personal litigation relating to spinal injury (worker's compensation is not an exclusion).
18. Have a current history of heavy smoking (more than one pack of cigarettes per day).
19. Currently reside in a location, or anticipating a potential relocation, that may interfere with completion of follow-up examinations.
20. Have mental illness or belonged to a vulnerable population, as determined by the investigator (e.g., prisoner or developmentally disabled), that would compromise ability to provide informed consent or compliance with follow-up requirements.
21. Have an uncontrolled seizure disorder.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Source
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DFW Center for Spinal Disorders
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONRI-OP-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.